Atrial Fibrillation Is Highly Prevalent Yet Undertreated in Patients With Biopsy-proven Nonalcoholic Steatohepatitis

Maureen Whitsett; Jane Wilcox; Amy Yang; Lihui Zhao; Mary Rinella; Lisa B. VanWagner


Liver International. 2019;39(5):933-940. 

In This Article


Atrial fibrillation prevalence is two-fold higher in patients with NASH and NASH cirrhosis compared to the general population. Patients with concurrent NASH and AF have a high burden of stroke, heart failure, diabetes and healthcare utilization. Nearly 40% of patients with NASH and AF do not receive guideline-recommended anticoagulation for stroke risk reduction based on the CHA2DS2VASc score. Future studies are needed to identify at-risk patients with NASH and AF, and to understand barriers, safety and clinical outcomes related to guideline-based management in the high-cardiovascular risk growing NASH population.